Integral Health Asset Management LLC Purchases New Shares in Arcellx, Inc. $ACLX

Integral Health Asset Management LLC purchased a new position in Arcellx, Inc. (NASDAQ:ACLX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 150,000 shares of the company’s stock, valued at approximately $12,315,000.

Other large investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock worth $1,893,000 after purchasing an additional 1,390 shares during the last quarter. Empowered Funds LLC purchased a new stake in Arcellx during the 1st quarter worth approximately $1,768,000. Intech Investment Management LLC increased its stake in Arcellx by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock worth $1,441,000 after buying an additional 4,760 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Arcellx in the 2nd quarter valued at $563,000. Finally, PNC Financial Services Group Inc. lifted its holdings in Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after purchasing an additional 486 shares in the last quarter. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Arcellx Stock Performance

ACLX opened at $114.39 on Friday. The stock has a market capitalization of $6.69 billion, a PE ratio of -28.11 and a beta of 0.23. Arcellx, Inc. has a one year low of $47.86 and a one year high of $114.80. The business’s 50 day moving average price is $81.66 and its 200 day moving average price is $79.18.

Arcellx (NASDAQ:ACLX) last posted its earnings results on Thursday, February 26th. The company reported ($1.01) EPS for the quarter, meeting analysts’ consensus estimates of ($1.01). Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%.The company had revenue of $1.65 million for the quarter, compared to the consensus estimate of $13.40 million. As a group, equities research analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ACLX shares. Stifel Nicolaus reaffirmed a “hold” rating and set a $115.00 target price (down from $127.00) on shares of Arcellx in a research note on Monday, February 23rd. UBS Group lowered shares of Arcellx from a “buy” rating to a “neutral” rating and raised their target price for the stock from $100.00 to $115.00 in a research note on Tuesday, February 24th. HC Wainwright lowered Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price target for the company. in a research report on Monday, February 23rd. Wells Fargo & Company downgraded Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective on the stock. in a research report on Monday, February 23rd. Finally, Leerink Partners restated a “market perform” rating and issued a $115.00 target price on shares of Arcellx in a report on Tuesday, February 24th. One research analyst has rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $111.87.

Insider Transactions at Arcellx

In other Arcellx news, insider Rami Elghandour sold 89,916 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the transaction, the insider owned 276,051 shares of the company’s stock, valued at $31,447,729.92. This trade represents a 24.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christopher Heery sold 7,437 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares in the company, valued at $1,941,126.81. This trade represents a 20.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 109,366 shares of company stock worth $11,526,708 in the last ninety days. 8.35% of the stock is currently owned by corporate insiders.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.